WHITE PLAINS, NY - Aug 20, 2025 - Iantrek, Inc., a pioneer in bio-interventional ophthalmic surgery, today announced the closing of a $42 million Series C financing round. This investment will accelerate the U.S. commercial launch of AlloFlo™ Uveo, the first interventional glaucoma therapy targeting the uveoscleral pathway, offering new hope for millions of patients facing limitations from existing treatments.
Funding Details
Iantrek secured $42 million in an oversubscribed Series C financing round, led by U.S. Venture Partners (USVP). The round saw participation from new investor aMoon Fund, alongside existing investors Visionary Ventures, Sectoral Asset Management, Radius Special Situations Fund, and Civilization Ventures. Announced on August 20, 2025, this brings Iantrek’s total funding to approximately $85 million. The capital infusion, based out of White Plains, NY, underscores strong investor confidence in Iantrek’s innovative approach to addressing unmet needs in glaucoma treatment.
Strategic Goals and Use of Funds
The Series C funding will primarily support the following organized priorities:
Commercial Launch Initiatives
- Full U.S. market rollout of AlloFlo™ Uveo, including marketing, distribution, and surgeon training programs.
- Expansion of early access programs, building on over 3,000 procedures already performed.
Pipeline Development and Expansion
- Advancement of next-generation products, such as AlloSert™ Uveo (uveoscleral spacer delivery platform), CanaloFlo™, and C.Rex™ (micro-interventional system for canal outflow enhancement).
- Completion of clinical trials and regulatory preparations for additional bio-interventional solutions, with a planned commercial launch in 2026.
Operational and Growth Objectives
- Scaling manufacturing capabilities to meet anticipated demand.
- Strengthening the team with key hires in sales, marketing, and R&D.
- Enhancing clinical evidence through ongoing registries and studies to demonstrate long-term efficacy and safety.
These efforts aim to position Iantrek as a leader in interventional glaucoma surgery, focusing on total-outflow enhancement and improved patient outcomes.
Historical Funding and Growth
| Round Type | Date | Amount Raised | Lead Investor(s) | Key Notes |
|---|---|---|---|---|
| Seed/Initial | 2019 (Founding) | Undisclosed | N/A | Early development funding to establish core technology platforms. |
| Series B | August 2022 | $23 million | Visionary Ventures | Oversubscribed round for MIGS device development and initial U.S. trials. |
| Bridge/Additional | February 2025 | $2.78 million | N/A | Supported controlled release stage and CEO transition. |
| Series C | August 2025 | $42 million | U.S. Venture Partners | Focused on commercial launch of AlloFlo™ Uveo and pipeline expansion. |
Iantrek has shown consistent growth since its founding in 2019, achieving milestones such as FDA clearances, over 2,000 procedures by May 2025, and positive 2-year clinical results demonstrating efficacy in glaucoma treatment.
Iantrek’s Technology
Iantrek specializes in bio-interventional and micro-interventional technologies for ophthalmic surgery, particularly minimally invasive glaucoma surgery (MIGS). Key innovations include:
- AlloFlo™ Uveo: The first allogeneic graft designed for durable implantation and bio-integration, targeting the uveoscleral pathway to enhance natural outflow and reduce intraocular pressure (IOP). Clinical data shows a 34% mean IOP reduction and over 60% decrease in medications after 2 years, with no serious adverse events.
- AlloSert™ Uveo: A delivery platform for uveoscleral spacers, enabling precise minimally invasive access.
- C.Rex™: A micro-interventional system for circumferential, excisional goniotomy, transforming canal outflow enhancement.
- CycloPen™: Ergonomically designed for controlled cyclodialysis creation, using homologous bio-tissue for scleral reinforcement.
- CanaloFlo™: Part of the pipeline for further outflow pathway improvements.
These technologies combine simplicity, precision, and bio-integration to address limitations in traditional glaucoma treatments.
Industry Impact and Challenges
Iantrek’s innovations are poised to significantly impact the ophthalmology field by providing new options for patients where trabecular-based MIGS procedures fail, affecting over 2.5 million eyes in the U.S. alone. By targeting the uveoscleral pathway—the eye’s secondary natural drainage system—AlloFlo™ Uveo offers a higher therapeutic index, potentially reducing the need for repeat surgeries and improving long-term outcomes.
Challenges in the glaucoma treatment landscape include waning efficacy of existing MIGS (e.g., due to scarring or limited outflow), high costs of chronic medication, and surgical risks like hypotony. Iantrek addresses these through bio-reinforced approaches that enhance durability and safety, as evidenced by 74% of treated eyes achieving ≥20% IOP reduction at 2 years with fewer medications. However, adoption may face hurdles like surgeon training and reimbursement complexities in a competitive MIGS market.
Market Context and Industry Trends
The global glaucoma surgical device market is experiencing rapid growth, projected to expand due to an aging population and rising glaucoma prevalence (affecting over 80 million worldwide). Key trends include:
- Shift toward minimally invasive procedures (MIGS) for earlier intervention, reducing reliance on drops or invasive surgeries.
- Focus on total-outflow enhancement, combining trabecular and uveoscleral pathways for better efficacy.
- Integration of bio-materials and allogeneic grafts for improved biocompatibility and longevity.
- Increasing clinical evidence demands, with registries like Iantrek’s CREST showing real-world data.
- Pipeline acceleration, with 18+ early-stage companies innovating in lasers and devices.
In this context, Iantrek’s bio-interventional platform aligns with trends toward personalized, durable treatments, positioning it to capture share in a market valuing innovation amid challenges like regulatory hurdles and competition from established players.
Stakeholder Insights
- Adam Szaronos, CEO of Iantrek: “This fundraise marks a pivotal moment in helping us achieve our mission to address a major unmet need in glaucoma care. The $42 million will enable the commercial launch of AlloFlo™ Uveo and advance our pipeline, bringing innovative solutions to millions of patients.”
- Casey Tansey, General Partner at USVP: “Leading this $42 million Series C round reflects our strong confidence in Iantrek’s disruptive approach. The funding will drive the commercial rollout of AlloFlo™ Uveo and position Iantrek as a leader in interventional glaucoma surgery.”
- Sean Ianchulev, MD, MPH, Chairman of the Board of Iantrek: “The $42 million Series C financing will accelerate our ability to scale AlloFlo™ Uveo’s early access program, which has already seen 3,000 procedures, and meet the clear demand for uveoscleral pathway interventions.”
- Todd Sone, General Partner at aMoon Fund: “Joining this oversubscribed Series C round, we’re excited to support Iantrek’s mission with this $42 million investment. The funding will fuel the commercial launch of AlloFlo™ Uveo and drive significant clinical value for glaucoma patients.”
About Iantrek
Iantrek, Inc. is a venture-funded medical technology company headquartered in White Plains, New York, founded in 2019 by ophthalmic innovator Sean Ianchulev, MD, MPH, Professor of Ophthalmology at the New York Eye and Ear of Mount Sinai. The company pioneers bio-interventional and micro-interventional products for ophthalmic surgery, with a focus on advancing interventional glaucoma treatments. Its portfolio includes AlloFlo™ Uveo, AlloSert™ Uveo, CycloPen™, C.Rex™, and CanaloFlo™—solutions designed to enhance the eye’s natural outflow pathways with precision and bio-integration. Iantrek’s mission is to redefine expectations in glaucoma surgery through breakthrough technologies that improve patient outcomes and surgical efficiency.
Future Outlook
Looking ahead, Iantrek plans a full commercial launch of AlloFlo™ Uveo in the U.S. later in 2025, followed by international expansion. The company has completed first-in-human trials for its next bio-interventional product, targeting a 2026 launch. With ongoing clinical registries and pipeline advancements, Iantrek aims to establish uveoscleral interventions as a standard in glaucoma care, potentially treating millions more patients and driving further innovation in total-outflow enhancement. Growth in procedures and partnerships will solidify its leadership in the evolving MIGS landscape.
Media Contact
Amy Phillips
amyphillipspr@gmail.com
